Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315380 · ClinicalTrials.gov registry record
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
A clinical trial of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 700
- Enrollment target
- 13
- Study locations
NCT00315380 is a study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 700 participants, above the 403-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (74% higher). The trial reports 13 study locations across 9 states.
The verdict
NCT00315380, a study of Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 13
- Study locations
Study Summary
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Conditions Studied
Study Locations (13)
Other
- medius KLINIK KIRCHHEIM - Kirchheim unter Teck
- AOU Meyer IRCCS - Florence
- Imperial College Healthcare NHS Trust/ Imperial College London - London
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh - Pittsburgh
Ontario
- St. Joseph's Healthcare - Hamilton
- Mount Sinai Hospital - Toronto
California
- University of California San Diego - San Diego
Colorado
- National Jewish Health - Denver
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2006-04 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315380
The ClinicalTrials.gov registry entry for NCT00315380 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 403-participant average among 3 other Eosinophilic Granulomatosis With Polyangiitis trials with a reported enrollment target (74% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Eosinophilic Granulomatosis With Polyangiitis appearing as the primary indexed condition, and to 0 interventions.
NCT00315380 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Other, Pennsylvania, Ontario.
Frequently Asked Questions
What is clinical trial NCT00315380 about?
NCT00315380 is a clinical study titled "Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis". Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level...
What is the current status of trial NCT00315380?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2006-04. Estimated completion is 2028-12.
What conditions does trial NCT00315380 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome.
Who is sponsoring clinical trial NCT00315380?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315380 being conducted?
This trial has 13 study locations across California, Colorado, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
RECRUITING · Phase 2
-
VCRC Tissue Repository
RECRUITING
-
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Eosinophilic Granulomatosis With Polyangiitis
All registered trials for this condition
Churg-Strauss Syndrome
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.